EP0822820A1 - NOUVELLE UTILISATION DE (S)-ADENOSYL-L-METHIONINE (SAMe) - Google Patents

NOUVELLE UTILISATION DE (S)-ADENOSYL-L-METHIONINE (SAMe)

Info

Publication number
EP0822820A1
EP0822820A1 EP96913500A EP96913500A EP0822820A1 EP 0822820 A1 EP0822820 A1 EP 0822820A1 EP 96913500 A EP96913500 A EP 96913500A EP 96913500 A EP96913500 A EP 96913500A EP 0822820 A1 EP0822820 A1 EP 0822820A1
Authority
EP
European Patent Office
Prior art keywords
same
patient
day
methionine
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96913500A
Other languages
German (de)
English (en)
Inventor
Georg Nemeth
Carlo Di Padova
Laszlo Szabo
Gerhard Gross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Publication of EP0822820A1 publication Critical patent/EP0822820A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • SAMe (S) -Adenosyl-L-methionine (SAMe) and its salts are already known, cf. EP-PS 162.323. It is also described that SAMe has a principal anti-ischemic effect (Eur. J. Pharmacol. 144: 211, 1987; Jpn. J. Pharmacol. 46: 225, 1988; Eur. J. Pharmacol. 166: 231, 1989; Jpn J. Pharmacol. 52: 141, 195 * 0). According to JP-PS 1,686,947, SAMe can be used for various indications relating to central damage. Daily doses of 100 mg to 1550 mg are given in this publication.
  • J. Pharmacol. 49, 119-124 (1989) describes the effect of SAMe on the Ca content and glucose metabolism and on mortality in rats after transient ischemia at doses of 100 mg / kg.
  • Acute embolic ischemia e.g. cardiac embolism, fatty
  • Thrombotic ischemia which includes the so-called cerebral
  • Ischemia Ischemias triggered by immunological, inflammatory mechanisms. This also includes focal ischemia caused by hemostasiological and immunological system diseases - focal ischemia, which are associated with special forms of vascular processes and other unusual causes. Traumatic brain and spinal injuries that lead directly or indirectly to focal ischemia (such as bulky intracerebral, subdural, ⁇ pidural ⁇ 'bleeding, brain contusions and laceration).
  • SAMe is preferably used in the form of a salt with a physiologically acceptable acid.
  • Preferred acids are: hydrochloric acid, sulfuric acid, phosphoric acid, formic acid, acetic acid, citric acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and butanedisulfonic acid.
  • SAMe or its salts are provided or recommended for the above-mentioned indication in an amount of at least 2000 mg / day / patient, in particular at least 3000 mg / day / patient and preferably in doses of at least 7000 mg / day / patient.
  • the indication of the high dose according to the invention is an essential lesson in the obvious preparation of the drug.
  • SAMe is administered parenterally (intravenously, intraarterially or intramuscularly) in a customary manner, with intravenous administration being the preferred form of administration.
  • the above amount can be infused into the patient over a period of 1 to 24 hours for several days.
  • Application forms which contain 6-18% by weight of SAMe together with lysine in water are particularly suitable for the use according to the invention.
  • Such an application form can, for example, be the following Composition: 400 mg SAMe, 324.3 mg L-lysine, 11.5 mg NaOH and 472.1 mg water for injections.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation de SAMe et de ses sels physiologiquement tolérables dans des doses supérieures à 2000 mg par jour et par patient, dans le traitement par voie parentérale de troubles dus à une ischémie permanente focale.
EP96913500A 1995-04-26 1996-04-13 NOUVELLE UTILISATION DE (S)-ADENOSYL-L-METHIONINE (SAMe) Withdrawn EP0822820A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19515275 1995-04-26
DE19515275A DE19515275A1 (de) 1995-04-26 1995-04-26 Neue Verwendung von (S)-Adenosyl-L-methionin(SAMe)
PCT/EP1996/001570 WO1996033727A1 (fr) 1995-04-26 1996-04-13 NOUVELLE UTILISATION DE (S)-ADENOSYL-L-METHIONINE (SAMe)

Publications (1)

Publication Number Publication Date
EP0822820A1 true EP0822820A1 (fr) 1998-02-11

Family

ID=7760373

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96913500A Withdrawn EP0822820A1 (fr) 1995-04-26 1996-04-13 NOUVELLE UTILISATION DE (S)-ADENOSYL-L-METHIONINE (SAMe)

Country Status (15)

Country Link
EP (1) EP0822820A1 (fr)
JP (1) JPH11504023A (fr)
KR (1) KR19990008061A (fr)
CN (1) CN1182367A (fr)
AR (1) AR001687A1 (fr)
AU (1) AU5646396A (fr)
CA (1) CA2216854A1 (fr)
CZ (1) CZ330597A3 (fr)
DE (1) DE19515275A1 (fr)
HR (1) HRP960196A2 (fr)
IL (1) IL117844A0 (fr)
MX (1) MX9707735A (fr)
NO (1) NO974941L (fr)
WO (1) WO1996033727A1 (fr)
ZA (1) ZA963296B (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE37913B1 (en) * 1972-08-02 1977-11-09 Bioresearch Sas Salt of s-adenosyl-l-methionine
JPS59139319A (ja) * 1983-01-31 1984-08-10 Fuji Kagaku Kogyo Kk 脳障害による身体機能障害治療剤
JPH02290896A (ja) * 1989-04-28 1990-11-30 Fuji Kagaku Kogyo Kk 新規なｓ―アデノシルメチオニン誘導体
DE4425280C2 (de) * 1994-07-16 1997-05-07 Knoll Ag Verwendung von (S)-Adenosyl-L-methionin und dessen physiologisch verträglichen Salzen zur Behandlung von Reperfusionsschäden, die nach temporärer fokaler Ischämie ausgelöst werden

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9633727A1 *

Also Published As

Publication number Publication date
NO974941D0 (no) 1997-10-24
AU5646396A (en) 1996-11-18
ZA963296B (en) 1997-10-27
WO1996033727A1 (fr) 1996-10-31
AR001687A1 (es) 1997-11-26
DE19515275A1 (de) 1996-10-31
HRP960196A2 (en) 1998-02-28
MX9707735A (es) 1997-12-31
CA2216854A1 (fr) 1996-10-13
KR19990008061A (ko) 1999-01-25
CZ330597A3 (cs) 1998-02-18
NO974941L (no) 1997-10-24
CN1182367A (zh) 1998-05-20
JPH11504023A (ja) 1999-04-06
IL117844A0 (en) 1996-08-04

Similar Documents

Publication Publication Date Title
DE69822665T2 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE3413052A1 (de) Pharmazeutische zubereitung und deren verwendung zur behandlung von hauterkrankungen
DE3317692A1 (de) Verwendung von metkephamid oder eines pharmazeutisch unbedenklichen salzes hiervon als analgetikum bei traechtigen weiblichen tieren und insbesondere bei schwangeren frauen
DE69834638T2 (de) Zusammensetzung zur Behandlung von Augenhypertension oder Glaukom
EP0108820A1 (fr) Solutions d'infusion pour le traitement du coeur
DE69303015T2 (de) Verwendung von phenothiazin-derivaten zur behandlung der ischämie und/oder der hypoxämie
DE2514335C3 (de) Oral zu verabreichendes Arzneimittel mit Antiplasmin-Inhibitorwirkung
DE69110615T2 (de) Verwendung von Aminosäuren zum Schutz von ischemischem Herzgewebe und dessen metabolischer Wiederherstellung.
DE3643119A1 (de) Therapeutische zusammensetzung fuer diabetes-komplikationen
DE60207442T2 (de) VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION
DE4425280C2 (de) Verwendung von (S)-Adenosyl-L-methionin und dessen physiologisch verträglichen Salzen zur Behandlung von Reperfusionsschäden, die nach temporärer fokaler Ischämie ausgelöst werden
EP0132595B1 (fr) Agent tocolytique
DE69937574T2 (de) Verwendung des pharmazeutischen präparates "histochrome" zur behandlung des akuten herzinfarkts und ischämischer herzerkrankungen
DE2750159C3 (de) Infusionslösung zur Behandlung von hepatischer Encephalopathie und ein Verfahren zu deren Herstellung
EP0350738A2 (fr) (S)-emopamil employée dans le traitement de la migraine
DE2611976A1 (de) Pharmazeutisches praeparat zur besserung und wiederherstellung bei verminderten bewusstseinszustaenden
EP0822820A1 (fr) NOUVELLE UTILISATION DE (S)-ADENOSYL-L-METHIONINE (SAMe)
DE2131679A1 (de) 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate
EP0013962A1 (fr) Solution d'infusion contenant des acides amino et des sels minéraux
EP0845264A1 (fr) Extrait partiel ou total de Camellia sinensis L. non fermenté
DE69909395T2 (de) Zusammensetzung mit ketanserin und carnitin zur behandlung von crps
DE60012183T2 (de) Verwendung einer makrolid-verbindung zur herstellung eines medikaments zur behandlung von gehirnschäden aufgrund von ischämie oder blutungen
DE19636252C2 (de) Pharmazeutisches Kombinationspräparat zur Behandlung von rheumatischen Erkrankungen
DE69114261T2 (de) Pharmazeutische zusammensetzungen zur behandlung der parkinson'schen krankheit.
DE3744542B4 (de) Pharmazeutische Verwendung von L-δ-Hydroxylysin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FI FR GB IT LI NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991103